Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer.

作者: C. Gessner , C. Woischwill , A. Schumacher , U. Liebers , H. Kuhn

DOI: 10.1183/09031936.03.00033203

关键词:

摘要: The human Y-box binding protein, YB-1, is a multifunctional protein that regulates gene expression. Nuclear expression of YB-1 has been associated with chemoresistance and poor prognosis tumour patients. Representative samples from autopsied material primary tumours 77 patients NSCLC were investigated by immunohistochemistry for subcellular distribution p53, in order to evaluate the prognostic role nuclear YB-1. Cytoplasmic was found all samples, whereas only observed 48%. There no correlation histological classification, clinical parameters or size, stage metastasis status. However, positive showed reduced survival times when compared without Including information about histology mutational status p53 increased value Patients mutations had worst (median 3 months), while best outcome wildtype 15 months). This suggests combined analysis both markers allows better identification subgroups varying prognosis. protien seems be an independent marker.

参考文章(27)
Herwart Müller, Ralf Hilger, Curative and palliative aspects of regional chemotherapy in combination with surgery. Supportive Care in Cancer. ,vol. 11, pp. 1- 10 ,(2003) , 10.1007/S00520-002-0355-2
L.K. Lacquet, The present status of surgery for lung cancer Acta Chirurgica Belgica. ,vol. 96, pp. 245- 251 ,(1996)
Takefumi Ohga, Mayumi Ono, Koji Koike, Michihiko Kuwano, Kimitoshi Kohno, Morimasa Tanimoto, Yasuharu Itagaki, Yoshinari Makino, Role of the Human Y Box-binding Protein YB-1 in Cellular Sensitivity to the DNA-damaging Agents Cisplatin, Mitomycin C, and Ultraviolet Light Cancer Research. ,vol. 56, pp. 4224- 4228 ,(1996)
Akio Sakamoto, Takeshi Uchiumi, Takefumi Ohga, Masazumi Tsuneyoshi, Yoshinao Oda, Norio Shinohara, Kimitoshi Kohno, Michihiko Kuwano, Yukihide Iwamoto, Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clinical Cancer Research. ,vol. 4, pp. 2273- 2277 ,(1998)
Yoshihiko Maehara, Yoshihiko Maehara, Kosei Yasumoto, Takeshi Uchiumi, Toshihiro Osaki, Michihiko Kuwano, Kimitoshi Kohno, Kotaro Shibahara, Kenji Sugio, Kenji Sugio, Keizo Sugimachi, Nuclear Expression of the Y-Box Binding Protein, YB-1, as a Novel Marker of Disease Progression in Non-Small Cell Lung Cancer Clinical Cancer Research. ,vol. 7, pp. 3151- 3155 ,(2001)
S. L. Parker, T. Tong, S. Bolden, P. A. Wingo, Cancer statistics, 1997 CA: A Cancer Journal for Clinicians. ,vol. 47, pp. 5- 27 ,(1997) , 10.3322/CANJCLIN.47.1.5
Nestor F Esnaola, Sophia N Lazarides, Steven J Mentzer, Karen M Kuntz, Outcomes and Cost-Effectiveness of Alternative Staging Strategies for Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 20, pp. 263- 273 ,(2002) , 10.1200/JCO.20.1.263
Yoshinao Oda, Yoshihiro Ohishi, Tsuyoshi Saito, Eiji Hinoshita, Takeshi Uchiumi, Naoko Kinukawa, Yukihide Iwamoto, Kimitoshi Kohno, Michihiko Kuwano, Masazumi Tsuneyoshi, Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma The Journal of Pathology. ,vol. 199, pp. 251- 258 ,(2003) , 10.1002/PATH.1282
Clifton F. Mountain, Revisions in the International System for Staging Lung Cancer Chest. ,vol. 111, pp. 1710- 1717 ,(1997) , 10.1378/CHEST.111.6.1710
Martin Janz, Nadia Harbeck, Peer Dettmar, Ursula Berger, Anja Schmidt, Karsten Jürchott, Manfred Schmitt, Hans-Dieter Royer, Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1 International Journal of Cancer. ,vol. 97, pp. 278- 282 ,(2002) , 10.1002/IJC.1610